通过多式数据估计临床前阿尔茨海默病的进展
Diana L Townsend1, Michael J Properzi1, Tobey J Betthauser2,3
1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|September 3, 2025
概括
认知时间 (c-time) 衡量一个人接近认知衰退的程度. 这一从纵向数据中得出的指标与临床前阿尔茨海默病中的β-粉样蛋白进展和大脑变化相关.
科学领域:
- 神经科学
- 生物统计学
- 老年学
背景情况:
- 在临床前阶段确定个体在阿尔茨海默病 (AD) 连续性的位置是具有挑战性的,因为基线是任意的.
- 纵向数据优化可以创建一个单一的指标来表示个体的疾病进展轨迹.
研究的目的:
- 使用纵向认知数据开发和验证"认知时间" (c-time) 度量.
- 评估c-time与已确定的AD病理标志物之间的关系,例如粉样β (Aβ) 沉积和神经退行.
主要方法:
- 通过对316名参与者的认知数据进行非线性最小平方优化开发了c-time度量.
- 从纵向粉样蛋白PET扫描中获得的c时间和粉样蛋白β阳性 (Aβ+) 度量之间的分析关联.
- 在路径分析中包括人口统计学,大脑体积,皮质厚度,TAU PET和心血管风险因素.
主要成果:
- C时间和Aβ+时间之间存在中等的正相关.
- 时间到Aβ+与c时间有直接和间接的关联,由区域性tau PET,海马体积和皮质厚度介导.
- 与Aβ+的时间相比,C时间与tau病理,大脑缩和皮质厚度的相关性更强.
结论:
- 优化纵向多式数据可以产生独立于年龄的指标,表明个体与疾病相关的事件的接近.
- C-time提供了一种新的方法来量化个体相对于认知衰退的开始.
- C-time为临床前AD连续性提供了宝贵的见解,整合了认知,病理和结构性大脑变化.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


